The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper echelons of the S&P 500 performance charts. This rally marks a definitive end to the "post-pandemic
In a move that signals a seismic shift in the global consumer goods sector, Kimberly-Clark (NYSE:KMB) is charging forward with its landmark $48.7 billion enterprise value acquisition of consumer health titan Kenvue (NYSE:KVUE). Announced in late 2025 and overwhelmingly approved by shareholders in January 2026, the deal
Amgen Inc. (NASDAQ: AMGN) and GSK plc (NYSE: GSK) are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs.
On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a household name during the COVID-19 pandemic, this latest rally signals a critical maturation point. Investors are no longer valuing Moderna solely on its [...]
Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level of investor enthusiasm not seen since the peak of the pandemic. While the broader markets remained relatively flat, Moderna’s spike was fueled by a convergence of positive clinical [...]
Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir (DOR/ISL). The data, presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026), confirms that the two-drug combination
On February 2, 2026, AstraZeneca PLC (NYSE: AZN) officially rang the opening bell at the New York Stock Exchange, marking the completion of its high-profile transition from the Nasdaq. The move signals a major structural shift for the UK-based pharmaceutical leader, as it moves away from its long-standing American Depositary
As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary arterial hypertension (PAH), the company has recently captured Wall Street’s attention with a series of high-stakes maneuvers. Following a stellar Q4 2025 earnings report released [...]
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir, now marketed as Yeztugo. As of February 25, 2026, the biopharmaceutical giant has successfully transitioned from a provider of daily oral regimens
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based biotechnology pioneer is now fighting to prove that its messenger RNA (mRNA) platform is a "one-hit wonder" no more. The company has dominated recent financial [...]
Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s expectations. Despite reporting a net loss, the company’s narrower-than-anticipated deficit of $2.11 per share and revenue of $678 million signaled
As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price growth and defense. While the technology sector continues to ride a wave of massive capital investment into artificial
Shares of Moderna, Inc. (NASDAQ: MRNA) fell 3.5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. The U.S. Food and Drug Administration (FDA) issued a Refusal-to-File (RTF) letter regarding the company’s Biologics License Application (BLA) for its
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the Delaware-based biopharmaceutical giant is currently undergoing a radical transformation. Today, the stock is under heavy scrutiny following yesterday’s fiscal year 2025 earnings report. While [...]
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the historic, yet short-lived, success of its Hepatitis C cures. However, as of early 2026, that narrative has shifted dramatically. Gilead has successfully executed a "second [...]
As of January 26, 2026, the American corporate landscape is undergoing its most radical transformation in a generation. Following a two-year period of high-interest-rate hibernation, the United States merger and acquisition (M&A) market has roared back to life with a ferocity that has caught even seasoned Wall Street analysts
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based biotechnology giant is now aggressively shedding its image as a "one-hit wonder" vaccine maker. Following a volatile 2024 and 2025, the company has captured Wall [...]
LONDON — January 20, 2026 — In a milestone moment for global capital markets, pharmaceutical giant AstraZeneca (NYSE: AZN) has officially filed its formal notice of voluntary withdrawal from the Nasdaq Stock Market today. The move marks the final countdown for one of the most significant listing migrations in recent history, as
As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results. This report serves as a critical barometer for the healthcare giant’s first full year as a
In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion. The deal, confirmed on January 20, 2026, represents a significant escalation in the multi-billion dollar race to dominate the
